Flash drug release from nanoparticles accumulated in the targeted blood vessels facilitates the tumour treatment

Ivan V. Zelepukin (), Olga Yu. Griaznova, Konstantin G. Shevchenko, Andrey V. Ivanov, Ekaterina V. Baidyuk, Natalia B. Serejnikova, Artur B. Volovetskiy, Sergey M. Deyev () and Andrei V. Zvyagin ()
Additional contact information
Ivan V. Zelepukin: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
Olga Yu. Griaznova: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
Konstantin G. Shevchenko: Institute of Cytology of the Russian Academy of Sciences
Andrey V. Ivanov: Sechenov First Moscow State Medical University (Sechenov University)
Ekaterina V. Baidyuk: Institute of Cytology of the Russian Academy of Sciences
Natalia B. Serejnikova: Sechenov First Moscow State Medical University (Sechenov University)
Artur B. Volovetskiy: Sechenov First Moscow State Medical University (Sechenov University)
Sergey M. Deyev: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
Andrei V. Zvyagin: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Nature Communications, 2022, vol. 13, issue 1, 1-15

Abstract: Abstract Tumour microenvironment hinders nanoparticle transport deep into the tissue precluding thorough treatment of solid tumours and metastatic nodes. We introduce an anticancer drug delivery concept termed FlaRE (Flash Release in Endothelium), which represents alternative to the existing approaches based on enhanced permeability and retention effect. This approach relies on enhanced drug-loaded nanocarrier accumulation in vessels of the target tumour or metastasised organ, followed by a rapid release of encapsulated drug within tens of minutes. It leads to a gradient-driven permeation of the drug to the target tissue. This pharmaceutical delivery approach is predicted by theoretical modelling and validated experimentally using rationally designed MIL-101(Fe) metal-organic frameworks. Doxorubicin-loaded MIL-101 nanoparticles get swiftly trapped in the vasculature of the metastasised lungs, disassemble in the blood vessels within 15 minutes and release drug, which rapidly impregnates the organ. A significant improvement of the therapeutic outcome is demonstrated in animal models of early and late-stage B16-F1 melanoma metastases with 11-fold and 4.3-fold decrease of pulmonary melanoma nodes, respectively.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-34718-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34718-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-34718-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().